Alba 
Sitemapcontactlogin 
HomePic.jpg
Technology Overview
Animation depicting the role of barrier function in disease pathology and Alba’s therapeutic approach through inhibition of increased paracellular permeability. View here »
IN THE NEWS

Alba Therapeutics Corporation is a Biopharmaceutical Company focused on the discovery, development and commercialization of therapeutics to treat autoimmune, immune mediated and inflammatory diseases. Alba’s technology provides the ability to transiently, physiologically and reversibly close or open the tight junctions of internal barriers such as the intestinal mucosa and pulmonary epithelia.  By altering paracellular permeability across these cell barriers, Alba seeks to develop therapeutic applications ranging from therapies for diseases associated with tight junction dysfunction and autoimmunity to vaccine adjuvancy and drug delivery. Read more »

Tuesday, November 11, 2008
Alba Therapeutics Corporation announced today that for the first time, a European patient with active celiac disease has been enrolled in its clinical trial to investigate a treatment for the disease. Read more » 

Wednesday, October 08, 2008
Alba Therapeutics Corporation presented results from two clinical studies this week at the American College of Gastroenterology (ACG) 2008 Annual Scientific Meeting.  Read more » 

Previous Press Releases
Copyright 2007 Alba Therapeutics Corporation. All Rights Reserved.Design: Round2